Biodesix (NASDAQ:BDSX) Releases Quarterly Earnings Results, Meets Estimates

Biodesix (NASDAQ:BDSX) announced its earnings results on Thursday. The company reported ($0.75) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.75), FiscalAI reports. The company had revenue of $24.04 million for the quarter, compared to analysts’ expectations of $27.49 million. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%.

Here are the key takeaways from Biodesix’s conference call:

• Biodesix reported Q3 revenue of $24.0 million, up 10%, and diagnostic test volume up 24%, but results fell short of expectations. Management attributed the shortfall to fewer sales representatives than planned, weaker-than-expected primary-care seasonality and delayed development-services projects.
• The company lowered its 2026 revenue outlook to $101 million–$103 million, or about 15% growth at the midpoint. Management expects development-services revenue to remain near $1 million in Q4, with many projects shifting into 2027; it also said a higher mix of Nodify CDT tests is weighing on average revenue per test.
• Commercial capacity has improved to about 110 representatives, with a target of 115 by year-end. Management said October was its strongest month of new-physician acquisition this year and expects added sales capacity and improved forecasting to support a recovery, while noting new hires take time to ramp.
• Biodesix cited the CHEST lung-nodule management framework and early enterprise-wide integrations at two major health systems as support for broader use of its Nodify tests. These system-level rollouts could make adoption more scalable, though management cautioned that implementation takes time.
• The company is expanding beyond blood-based diagnostics with a radiomic lung-nodule test targeted for commercialization in 2028 and two MRD assay programs developed with Bio-Rad and Thermo Fisher. These initiatives broaden its longer-term opportunity, but remain in development.

Biodesix Stock Performance

Shares of BDSX stock opened at $8.53 on Friday. Biodesix has a 52 week low of $5.26 and a 52 week high of $31.97. The firm has a market capitalization of $89.99 million, a PE ratio of -3.09 and a beta of 0.65. The company has a 50 day moving average price of $25.53 and a 200-day moving average price of $18.90. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12.

Analyst Ratings Changes

BDSX has been the subject of a number of analyst reports. Canaccord Genuity Group boosted their price objective on shares of Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, August 10th. HC Wainwright reaffirmed a “buy” rating on shares of Biodesix in a report on Thursday, October 22nd. Weiss Ratings upgraded shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 8th. Finally, TD Cowen reissued a “buy” rating and set a $40.00 price target (up from $30.00) on shares of Biodesix in a research note on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $36.25.

Insider Activity at Biodesix

In other news, Director Jack Schuler bought 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was bought at an average price of $24.47 per share, with a total value of $367,050.00. Following the completion of the transaction, the director directly owned 555,810 shares of the company’s stock, valued at approximately $13,600,670.70. The trade was a 2.77% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have bought 42,600 shares of company stock valued at $1,033,062 in the last quarter. Corporate insiders own 23.20% of the company’s stock.

Biodesix News Roundup

Here are the key news stories impacting Biodesix this week:

• Neutral Sentiment: Biodesix plans to end 2026 with approximately 115 sales representatives, an effort to expand its commercial reach. Article
• Negative Sentiment: Third-quarter revenue was $24.04 million, below analysts’ estimate of $27.49 million. Biodesix reported a loss of $0.75 per share; one cited consensus was $0.75, while Zacks reported a $0.74 estimate. Article
• Negative Sentiment: For 2026, the company forecast revenue of $101 million to $103 million, below the $111.7 million analyst consensus—signaling a weaker outlook than investors had expected. Article
• Negative Sentiment: Biodesix disclosed the departure of Chief Commercial Officer Ki…; the leadership change may add uncertainty as the company works to grow sales. Article
• Negative Sentiment: Following the sharp decline, Johnson Fistel said it had opened an investigation into whether Biodesix or its officers made misleading statements or failed to disclose material information. This is an investigation, not a finding of wrongdoing. Article

About Biodesix

Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions.

Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.